Fred D. Lublin
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Fred D. Lublin has a total of 314 co-authors. Here are the top co-authors by number of shared publications:
- Ludwig Kappos
University Hospital Basel, Switzerland
8 shared publications - Gavin Giovannoni
Blizard Institute, Faculty of Medicine and Dentistry, Queen Mary University of London, London, UK
5 shared publications - Alan J. Thompson
Queen Square Multiple Sclerosis Centre, Department of Neuroinflammation, UCL Institute of Neurology, London, United Kingdom
4 shared publications - Flavia Nelson
CNS Autoimmune Disorders Division, Neurology Department, University of Miami, Miami, USA
4 shared publications - Gary Cutter
Department of Biostatistics, University of Alabama at Birmingham, Birmingham, AL, USA
4 shared publications Aaron Miller
3 shared publications
Latest Publications
- 3 August 2026
- Published by Springer Nature in Nature Reviews Neurology
- Vol. 22 (10) , 652-660
Towards a biologically informed description of multiple sclerosis disease course — a roadmap for transition
- 3 August 2026
- Published by Springer Nature in Nature Reviews Neurology
- Vol. 22 (10) , 652-660
Towards a biologically informed description of multiple sclerosis disease course — a roadmap for transition
- Open Access
- 26 November 2025
- Published by Oxford University Press (OUP) in Brain
- Vol. 149 (5) , 1732-1749
Cognition in multiple sclerosis within the modern diagnostic and treatment era
Slowed information processing speed has long been considered the principal cognitive deficit in multiple sclerosis, with slowed cognitive speed presumed responsible for downstream deficits in other functions, including memory. This speed-centric model was established over three decades ago before disease-modifying therapies were available, and contrasts with our current clinical experience, but nonetheless remains dominant and unquestioned. We re-evaluated this model among current patients with multiple sclerosis diagnosed and cared for within the modern diagnostic and treatment era (2001–25). Within a case-control cohort, persons with early relapsing-remitting disease (≤5.0 years since diagnosis, n = 170) performed worse than neurologically-healthy controls (n = 45) on memory but not cognitive speed, and cognitive speed among patients remained normal and stable over the next 6 years despite subtle memory decline. Relative to four historical studies of early relapsing-remitting disease (diagnosed using older criteria), effect sizes for case-control differences in our cohort were much lower for cognitive speed, but comparable for memory. An independent clinical cohort of 1004 consecutive patients aged 18–65 years with relapse-onset multiple sclerosis completed standard-of-care cognitive screenings between 2018 and 2025. We captured data from three independent periods. During the first period (n = 642), rates of poor performance (≤7.5th percentile) did not differ from normative expectations for cognitive speed (8.4%) or attention (9.0%), but were nonetheless elevated for verbal memory (23.8%) and visuospatial memory (14.8%). Patients during the second (n = 123) and third (n = 239) periods demonstrated memory deficits despite normal cognitive speed on co-normed tasks. Objective cognitive speed among current patients was remarkably similar to healthy normative expectations [z-score: mean (standard deviation), 0.03 (1.14); median (interquartile range), 0.00 (−0.67, 0.67)], and was much better than across several historical comparisons from 20–25 years ago. Self-reported cognitive deficits within the total clinical cohort versus control respondents indicated worst disease-related difficulties in expressive language (e.g. word-finding), followed by working memory and episodic memory, with a small difference in executive/speed that was fully explained by mood in relapsing-remitting disease. Current patient-reported attention/executive deficits were lower than 35 years ago, despite comparable memory difficulties. As an exception, attention/executive and cognitive speed deficits were observed in secondary-progressive disease. The speed-centric model of cognitive dysfunction in multiple sclerosis is inaccurate within the modern diagnostic and treatment era. Memory deficits remain prevalent, and we highlight working memory maintenance as an important target for further investigation. The field requires testable models of memory dysfunction informed by contemporary cognitive neuroscience, with the goal of developing heretofore elusive treatments for memory deficits.
- 26 November 2025
- Published by Oxford University Press (OUP) in Brain
- Vol. 149 (5) , 1732-1749
Open AccessCognition in multiple sclerosis within the modern diagnostic and treatment era
Slowed information processing speed has long been considered the principal cognitive deficit in multiple sclerosis, with slowed cognitive speed presumed responsible for downstream deficits in other functions, including memory. This speed-centric model was established over three decades ago before disease-modifying therapies were available, and contrasts with our current clinical experience, but nonetheless remains dominant and unquestioned. We re-evaluated this model among current patients with multiple sclerosis diagnosed and cared for within the modern diagnostic and treatment era (2001–25). Within a case-control cohort, persons with early relapsing-remitting disease (≤5.0 years since diagnosis, n = 170) performed worse than neurologically-healthy controls (n = 45) on memory but not cognitive speed, and cognitive speed among patients remained normal and stable over the next 6 years despite subtle memory decline. Relative to four historical studies of early relapsing-remitting disease (diagnosed using older criteria), effect sizes for case-control differences in our cohort were much lower for cognitive speed, but comparable for memory. An independent clinical cohort of 1004 consecutive patients aged 18–65 years with relapse-onset multiple sclerosis completed standard-of-care cognitive screenings between 2018 and 2025. We captured data from three independent periods. During the first period (n = 642), rates of poor performance (≤7.5th percentile) did not differ from normative expectations for cognitive speed (8.4%) or attention (9.0%), but were nonetheless elevated for verbal memory (23.8%) and visuospatial memory (14.8%). Patients during the second (n = 123) and third (n = 239) periods demonstrated memory deficits despite normal cognitive speed on co-normed tasks. Objective cognitive speed among current patients was remarkably similar to healthy normative expectations [z-score: mean (standard deviation), 0.03 (1.14); median (interquartile range), 0.00 (−0.67, 0.67)], and was much better than across several historical comparisons from 20–25 years ago. Self-reported cognitive deficits within the total clinical cohort versus control respondents indicated worst disease-related difficulties in expressive language (e.g. word-finding), followed by working memory and episodic memory, with a small difference in executive/speed that was fully explained by mood in relapsing-remitting disease. Current patient-reported attention/executive deficits were lower than 35 years ago, despite comparable memory difficulties. As an exception, attention/executive and cognitive speed deficits were observed in secondary-progressive disease. The speed-centric model of cognitive dysfunction in multiple sclerosis is inaccurate within the modern diagnostic and treatment era. Memory deficits remain prevalent, and we highlight working memory maintenance as an important target for further investigation. The field requires testable models of memory dysfunction informed by contemporary cognitive neuroscience, with the goal of developing heretofore elusive treatments for memory deficits.
- Top Cited PapersOpen Access
- 20 August 2025
- Published by Springer Nature in Nature Medicine
- Vol. 31 (10) , 3414-3424
AI-driven reclassification of multiple sclerosis progression
Multiple sclerosis (MS) affects 2.9 million people. Traditional classification of MS into distinct subtypes poorly reflects its pathobiology and has limited value for prognosticating disease evolution and treatment response, thereby hampering drug discovery. Here we report a data-driven classification of MS disease evolution by analyzing a large clinical trial database (approximately 8,000 patients, 118,000 patient visits and more than 35,000 magnetic resonance imaging scans) using probabilistic machine learning. Four dimensions define MS disease states: physical disability, brain damage, relapse and subclinical disease activity. Early/mild/evolving (EME) MS and advanced MS represent two poles of a disease severity spectrum. Patients with EME MS show limited clinical impairment and minor brain damage. Transitions to advanced MS occur via brain damage accumulation through inflammatory states, with or without accompanying symptoms. Advanced MS is characterized by moderate to high disability levels, radiological disease burden and risk of disease progression independent of relapses, with little probability of returning to earlier MS states. We validated these results in an independent clinical trial database and a real-world cohort, totaling more than 4,000 patients with MS. Our findings support viewing MS as a disease continuum. We propose a streamlined disease classification to offer a unifying understanding of the disease, improve patient management and enhance drug discovery efficiency and precision.
- 20 August 2025
- Published by Springer Nature in Nature Medicine
- Vol. 31 (10) , 3414-3424
Top Cited PapersOpen AccessAI-driven reclassification of multiple sclerosis progression
Multiple sclerosis (MS) affects 2.9 million people. Traditional classification of MS into distinct subtypes poorly reflects its pathobiology and has limited value for prognosticating disease evolution and treatment response, thereby hampering drug discovery. Here we report a data-driven classification of MS disease evolution by analyzing a large clinical trial database (approximately 8,000 patients, 118,000 patient visits and more than 35,000 magnetic resonance imaging scans) using probabilistic machine learning. Four dimensions define MS disease states: physical disability, brain damage, relapse and subclinical disease activity. Early/mild/evolving (EME) MS and advanced MS represent two poles of a disease severity spectrum. Patients with EME MS show limited clinical impairment and minor brain damage. Transitions to advanced MS occur via brain damage accumulation through inflammatory states, with or without accompanying symptoms. Advanced MS is characterized by moderate to high disability levels, radiological disease burden and risk of disease progression independent of relapses, with little probability of returning to earlier MS states. We validated these results in an independent clinical trial database and a real-world cohort, totaling more than 4,000 patients with MS. Our findings support viewing MS as a disease continuum. We propose a streamlined disease classification to offer a unifying understanding of the disease, improve patient management and enhance drug discovery efficiency and precision.
- Open Access
- 27 May 2025
- Published by Wolters Kluwer Health in Neurology
- Vol. 104 (10) , e213558
Composite Confirmed Disability Worsening/Progression Is a Useful Clinical Endpoint for Multiple Sclerosis Clinical Trials
Sensitive and meaningful disability worsening measures remain an unmet medical need in multiple sclerosis (MS). Composite confirmed disability worsening/progression (cCDW/cCDP) combines the Expanded Disability Status Scale (EDSS) with performance tests of ambulation and dexterity (Timed 25-Foot Walk Test [T25FWT] and Nine-Hole Peg Test [9HPT]). We assessed the relation of changes in these measures to understand the utility of cCDW/cCDP as an endpoint for MS trials. Clinical trials measuring all components of cCDW were selected for the analysis of (i) individual patient-level data from Roche-sponsored MS studies to characterize the association between performance-test changes and subsequent EDSS changes and (ii) population-level data from published studies reporting treatment effects on EDSS and either cCDP or T25FWT or 9HPT events to examine the relationship between treatment effects on T25FWT and EDSS events. Analysis (i): 6 Roche-sponsored Phase III trials comprising 4,979 patients with relapsing-remitting MS (RRMS; n = 1,225), relapsing MS (RMS; n = 1,656), progressive MS (PMS; n = 922), and primary progressive MS (PPMS; n = 1,171), with a data cutoff of November 2022, were included in the individual patient analyses. For all trials, T25FWT events were associated with increased risk of subsequent EDSS events (hazard ratios [HRs], p values: 2.11-5.20, 0.07-p values from 0.24-p values: T25FWT 1.74-3.26, 0.01-p values: T25FWT 1.45-2.17, 0.004-p = 0.005). In this post hoc analysis, worsening on T25FWT or 9HPT was a harbinger of EDSS worsening and treatment effects on T25FWT correlated with those on EDSS. These results establish the predictive validity and clinical relevance of performance-test worsening, thus supporting use of cCDW/cCDP as a primary outcome for progression in MS trials. ClinicalTrials.gov Identifiers: NCT01247324 (OPERA I); first submitted November 23, 2010; first patient enrolled: August 31, 2011; available at clinicaltrials.gov/study/NCT01247324. NCT01412333 (OPERA II); first submitted August 8, 2011; first patient enrolled: September 20, 2011; available at clinicaltrials.gov/study/NCT01412333. NCT03085810 (ENSEMBLE); first submitted March 16, 2017; first patient enrolled: March 27, 2017; available at clinicaltrials.gov/study/NCT03085810. NCT01194570 (ORATORIO); first submitted August 28, 2010; first patient enrolled: March 3, 2011; available at clinicaltrials.gov/study/NCT01194570. NCT03523858 (CONSONANCE); first submitted April 16, 2018; first patient enrolled: May 28, 2018; available at clinicaltrials.gov/study/NCT03523858. NCT00087529 (OLYMPUS); first submitted July 9, 2004; first patient enrolled: July 9, 2004; available at clinicaltrials.gov/study/NCT00087529.
- 27 May 2025
- Published by Wolters Kluwer Health in Neurology
- Vol. 104 (10) , e213558
Open AccessComposite Confirmed Disability Worsening/Progression Is a Useful Clinical Endpoint for Multiple Sclerosis Clinical Trials
Sensitive and meaningful disability worsening measures remain an unmet medical need in multiple sclerosis (MS). Composite confirmed disability worsening/progression (cCDW/cCDP) combines the Expanded Disability Status Scale (EDSS) with performance tests of ambulation and dexterity (Timed 25-Foot Walk Test [T25FWT] and Nine-Hole Peg Test [9HPT]). We assessed the relation of changes in these measures to understand the utility of cCDW/cCDP as an endpoint for MS trials. Clinical trials measuring all components of cCDW were selected for the analysis of (i) individual patient-level data from Roche-sponsored MS studies to characterize the association between performance-test changes and subsequent EDSS changes and (ii) population-level data from published studies reporting treatment effects on EDSS and either cCDP or T25FWT or 9HPT events to examine the relationship between treatment effects on T25FWT and EDSS events. Analysis (i): 6 Roche-sponsored Phase III trials comprising 4,979 patients with relapsing-remitting MS (RRMS; n = 1,225), relapsing MS (RMS; n = 1,656), progressive MS (PMS; n = 922), and primary progressive MS (PPMS; n = 1,171), with a data cutoff of November 2022, were included in the individual patient analyses. For all trials, T25FWT events were associated with increased risk of subsequent EDSS events (hazard ratios [HRs], p values: 2.11-5.20, 0.07-p values from 0.24-p values: T25FWT 1.74-3.26, 0.01-p values: T25FWT 1.45-2.17, 0.004-p = 0.005). In this post hoc analysis, worsening on T25FWT or 9HPT was a harbinger of EDSS worsening and treatment effects on T25FWT correlated with those on EDSS. These results establish the predictive validity and clinical relevance of performance-test worsening, thus supporting use of cCDW/cCDP as a primary outcome for progression in MS trials. ClinicalTrials.gov Identifiers: NCT01247324 (OPERA I); first submitted November 23, 2010; first patient enrolled: August 31, 2011; available at clinicaltrials.gov/study/NCT01247324. NCT01412333 (OPERA II); first submitted August 8, 2011; first patient enrolled: September 20, 2011; available at clinicaltrials.gov/study/NCT01412333. NCT03085810 (ENSEMBLE); first submitted March 16, 2017; first patient enrolled: March 27, 2017; available at clinicaltrials.gov/study/NCT03085810. NCT01194570 (ORATORIO); first submitted August 28, 2010; first patient enrolled: March 3, 2011; available at clinicaltrials.gov/study/NCT01194570. NCT03523858 (CONSONANCE); first submitted April 16, 2018; first patient enrolled: May 28, 2018; available at clinicaltrials.gov/study/NCT03523858. NCT00087529 (OLYMPUS); first submitted July 9, 2004; first patient enrolled: July 9, 2004; available at clinicaltrials.gov/study/NCT00087529.
- Open Access
- 24 December 2024
- Published by Oxford University Press (OUP) in Brain Communications
- Vol. 7 (1) , fcae446
Relationship between sodium and diffusion MRI metrics in multiple sclerosis
Sodium MRI can measure in vivo sodium concentrations in people with multiple sclerosis, but the extent to which these alterations reflect metabolic dysfunction in the absence of tissue damage or neuroaxonal loss remains uncertain. Increases in total sodium concentration and extracellular sodium concentration are believed to be indicative of tissue disruption and extracellular space expansion. Conversely, increase in intracellular sodium concentration may represent early and transient responses to neuronal insult, preceding overt tissue damage. Here, we explored the relationship between total sodium concentration, intracellular sodium concentration and intracellular sodium volume fraction, which reflects extracellular sodium concentration, against histology-validated microstructural metrics obtained using diffusion MRI. Fifty-two individuals with multiple sclerosis and 26 healthy controls underwent 1H/23Na MRI. Microstructural parameters were derived using Diffusion Basis Spectrum Imaging and Neurite Orientation Dispersion and Density-Imaging models. A progressive worsening in total sodium concentration and intracellular sodium volume fraction was observed from HCs white matter to normal-appearing white matter and further into T2-hyperintense and T1-hypointense lesions. Both total sodium concentration and intracellular sodium volume fraction, but not intracellular sodium concentration, correlated with Neurite Orientation Dispersion and Density Imaging and Diffusion Basis Spectrum Imaging metrics within multiple sclerosis lesions. Our findings confirm the utility of total sodium concentration and extracellular sodium concentration as indicators of extracellular expansion and axonal loss and underscore intracellular sodium concentration as a valuable biomarker for metabolic dysfunction in multiple sclerosis.
- 24 December 2024
- Published by Oxford University Press (OUP) in Brain Communications
- Vol. 7 (1) , fcae446
Open AccessRelationship between sodium and diffusion MRI metrics in multiple sclerosis
Sodium MRI can measure in vivo sodium concentrations in people with multiple sclerosis, but the extent to which these alterations reflect metabolic dysfunction in the absence of tissue damage or neuroaxonal loss remains uncertain. Increases in total sodium concentration and extracellular sodium concentration are believed to be indicative of tissue disruption and extracellular space expansion. Conversely, increase in intracellular sodium concentration may represent early and transient responses to neuronal insult, preceding overt tissue damage. Here, we explored the relationship between total sodium concentration, intracellular sodium concentration and intracellular sodium volume fraction, which reflects extracellular sodium concentration, against histology-validated microstructural metrics obtained using diffusion MRI. Fifty-two individuals with multiple sclerosis and 26 healthy controls underwent 1H/23Na MRI. Microstructural parameters were derived using Diffusion Basis Spectrum Imaging and Neurite Orientation Dispersion and Density-Imaging models. A progressive worsening in total sodium concentration and intracellular sodium volume fraction was observed from HCs white matter to normal-appearing white matter and further into T2-hyperintense and T1-hypointense lesions. Both total sodium concentration and intracellular sodium volume fraction, but not intracellular sodium concentration, correlated with Neurite Orientation Dispersion and Density Imaging and Diffusion Basis Spectrum Imaging metrics within multiple sclerosis lesions. Our findings confirm the utility of total sodium concentration and extracellular sodium concentration as indicators of extracellular expansion and axonal loss and underscore intracellular sodium concentration as a valuable biomarker for metabolic dysfunction in multiple sclerosis.
- 25 April 2023
- Published by Wolters Kluwer Health in Neurology
- Vol. 100 (17_supplem)
Longitudinal Clinical and MRI Outcomes in Relapsing Multiple Sclerosis (RMS) Patients After Short-term Ponesimod Treatment Interruption and Re-initiation (P6-3.007)
Objective: To assess clinical and magnetic resonance imaging (MRI) outcomes in RMS patients at 48 weeks of follow-up after short-term interruption and re-initiation of ponesimod treatment. Background: Current multiple sclerosis (MS) disease-modifying treatments alter patients’ immune system due to different pharmacokinetic/pharmacodynamic profiles. Clinical situations such as pregnancies, infections or live vaccinations may require rapid drug elimination and a fully functioning immune system. Lymphocyte counts return to normal range in >90% of patients within 1 week of stopping ponesimod treatment. It is important to evaluate MS disease activity over time following ponesimod treatment interruption and re-initiation. Design/Methods: Patients who completed 108 weeks of ponesimod or teriflunomide treatment in the Phase-3 OPTIMUM study and underwent an accelerated elimination procedure were eligible for the open-label extension (OLE) study and received ponesimod 20mg. Of 567 patients randomized to ponesimod in OPTIMUM, 439 (77.4%) entered the OLE and 239 (42.2%) had ≥48 weeks of follow up. The annualized relapse rate (ARR) and cumulative number of combined-unique-active-lesions (CUALs) following short-term treatment interruption (between OPTIMUM and OLE) and re-initiation (at start of the OLE) were evaluated in 239 patients. Results: The mean duration of ponesimod treatment interruption (between the end of OPTIMUM and initiation of OLE) was 17.6 days (range 13–45). The ARR at OLE week 48, and considering treatment interruption and re-initiation, was 0.191 (95% CI:0.140, 0.261). This was numerically lower than the 2-year ARR of 0.234 (95% CI: 0.186, 0.296) with a relative rate reduction (RRR) of 18.4% (RRR: 0.816, 95% CI: 0.595, 1.120). At OLE week 48, patients had 1.73 CUALs/year (95% CI:1.30, 2.31), which was not statistically significantly different from 1.48 CUALs/year (95% CI: 1.19, 1.82) in OPTIMUM. Conclusions: Based on clinical and imaging outcomes at 48 weeks following short-term interruption and re-initiation of ponesimod, disease activity remained consistent with that observed prior to interruption. Disclosure: Alexander Keenan has received personal compensation for serving as an employee of Janssen Pharmaceuticals. Alexander Keenan has received stock or an ownership interest from Johnson and Johnson. The institution of Dr. Kappos has received research support from Bayer. The institution of Dr. Kappos has received research support from Biogen. The institution of Dr. Kappos has received research support from Genentech. The institution of Dr. Kappos has received research support from Genzyme. The institution of Dr. Kappos has received research support from Janssen. The institution of Dr. Kappos has received research support from Merck Serono. The institution of Dr. Kappos has received research support from Minoryx. The institution of Dr. Kappos has received research support from Novartis. The institution of Dr. Kappos has received research support from Roche. The institution of Dr. Kappos has received research support from Sanofi. The institution of Dr. Kappos has received research support from Santhera. The institution of Dr. Kappos has received research support from Swiss MS Society, Swiss National Research Foundation, European Union, Roche Research Foundation, Innosuisse. The institution of Dr. Kappos has received research support from Shionogi. The institution of Dr. Kappos has received research support from Japan Tobacco. The institution of Dr. Kappos has received research support from Auriga Vision AG. The institution of Dr. Kappos has received research support from EMD Serono. The institution of Dr. Kappos has received research support from Glaxo Smith Kline. The institution of Dr. Kappos has received research support from Wellmera AG. The institution of Dr. Kappos has received research support from Eli Lilly (Suisse) SA. The institution of Dr. Kappos has received research support from Bristol Myers Squibb. The institution of Dr. Kappos has received research support from Celltrion Inc. Dr. Kappos has received intellectual property interests from a discovery or technology relating to health care. Dr. Ait Tihyaty has received personal compensation for serving as an employee of Janssen. Ms. Gandhi has received personal compensation for serving as an employee of Janssen Pharmaceuticals. Ms. Gandhi has received personal compensation for serving as an employee of Pfizer. An immediate family member of Ms. Gandhi has received personal compensation for serving as an employee of AstraZeneca LLC. Ms. Gandhi has stock in Janssen Pharmaceuticals. An immediate family member of Ms. Gandhi has stock in AstraZeneca LLC. Dr. Turkoz has received personal compensation for serving as an employee of Janssen R&D. Dr. Turkoz has received stock or an ownership interest from J&J. Dr. Wong has received personal compensation for serving as an employee of Janssen Research & Development. Dr. Wong has received personal compensation for serving as an employee of Biogen. Dr. Wong has stock in Biogen. Dr. Sidorenko has received personal compensation for serving as an employee of Actelion Pharmaceuticals Ltd, a Janssen Pharmaceutical company of Johnson&Johnson. Dr. Sidorenko has stock in Johnson&Johnson. Dr. Lublin has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Roche/Genentech. Dr. Lublin has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Biogen. Dr. Lublin has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Neurogene. Dr. Lublin has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Novartis. Dr. Lublin has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Medimmune/Viela Bio/Horizon. Dr. Lublin has received personal...
- 25 April 2023
- Published by Wolters Kluwer Health in Neurology
- Vol. 100 (17_supplem)
Longitudinal Clinical and MRI Outcomes in Relapsing Multiple Sclerosis (RMS) Patients After Short-term Ponesimod Treatment Interruption and Re-initiation (P6-3.007)
Objective: To assess clinical and magnetic resonance imaging (MRI) outcomes in RMS patients at 48 weeks of follow-up after short-term interruption and re-initiation of ponesimod treatment. Background: Current multiple sclerosis (MS) disease-modifying treatments alter patients’ immune system due to different pharmacokinetic/pharmacodynamic profiles. Clinical situations such as pregnancies, infections or live vaccinations may require rapid drug elimination and a fully functioning immune system. Lymphocyte counts return to normal range in >90% of patients within 1 week of stopping ponesimod treatment. It is important to evaluate MS disease activity over time following ponesimod treatment interruption and re-initiation. Design/Methods: Patients who completed 108 weeks of ponesimod or teriflunomide treatment in the Phase-3 OPTIMUM study and underwent an accelerated elimination procedure were eligible for the open-label extension (OLE) study and received ponesimod 20mg. Of 567 patients randomized to ponesimod in OPTIMUM, 439 (77.4%) entered the OLE and 239 (42.2%) had ≥48 weeks of follow up. The annualized relapse rate (ARR) and cumulative number of combined-unique-active-lesions (CUALs) following short-term treatment interruption (between OPTIMUM and OLE) and re-initiation (at start of the OLE) were evaluated in 239 patients. Results: The mean duration of ponesimod treatment interruption (between the end of OPTIMUM and initiation of OLE) was 17.6 days (range 13–45). The ARR at OLE week 48, and considering treatment interruption and re-initiation, was 0.191 (95% CI:0.140, 0.261). This was numerically lower than the 2-year ARR of 0.234 (95% CI: 0.186, 0.296) with a relative rate reduction (RRR) of 18.4% (RRR: 0.816, 95% CI: 0.595, 1.120). At OLE week 48, patients had 1.73 CUALs/year (95% CI:1.30, 2.31), which was not statistically significantly different from 1.48 CUALs/year (95% CI: 1.19, 1.82) in OPTIMUM. Conclusions: Based on clinical and imaging outcomes at 48 weeks following short-term interruption and re-initiation of ponesimod, disease activity remained consistent with that observed prior to interruption. Disclosure: Alexander Keenan has received personal compensation for serving as an employee of Janssen Pharmaceuticals. Alexander Keenan has received stock or an ownership interest from Johnson and Johnson. The institution of Dr. Kappos has received research support from Bayer. The institution of Dr. Kappos has received research support from Biogen. The institution of Dr. Kappos has received research support from Genentech. The institution of Dr. Kappos has received research support from Genzyme. The institution of Dr. Kappos has received research support from Janssen. The institution of Dr. Kappos has received research support from Merck Serono. The institution of Dr. Kappos has received research support from Minoryx. The institution of Dr. Kappos has received research support from Novartis. The institution of Dr. Kappos has received research support from Roche. The institution of Dr. Kappos has received research support from Sanofi. The institution of Dr. Kappos has received research support from Santhera. The institution of Dr. Kappos has received research support from Swiss MS Society, Swiss National Research Foundation, European Union, Roche Research Foundation, Innosuisse. The institution of Dr. Kappos has received research support from Shionogi. The institution of Dr. Kappos has received research support from Japan Tobacco. The institution of Dr. Kappos has received research support from Auriga Vision AG. The institution of Dr. Kappos has received research support from EMD Serono. The institution of Dr. Kappos has received research support from Glaxo Smith Kline. The institution of Dr. Kappos has received research support from Wellmera AG. The institution of Dr. Kappos has received research support from Eli Lilly (Suisse) SA. The institution of Dr. Kappos has received research support from Bristol Myers Squibb. The institution of Dr. Kappos has received research support from Celltrion Inc. Dr. Kappos has received intellectual property interests from a discovery or technology relating to health care. Dr. Ait Tihyaty has received personal compensation for serving as an employee of Janssen. Ms. Gandhi has received personal compensation for serving as an employee of Janssen Pharmaceuticals. Ms. Gandhi has received personal compensation for serving as an employee of Pfizer. An immediate family member of Ms. Gandhi has received personal compensation for serving as an employee of AstraZeneca LLC. Ms. Gandhi has stock in Janssen Pharmaceuticals. An immediate family member of Ms. Gandhi has stock in AstraZeneca LLC. Dr. Turkoz has received personal compensation for serving as an employee of Janssen R&D. Dr. Turkoz has received stock or an ownership interest from J&J. Dr. Wong has received personal compensation for serving as an employee of Janssen Research & Development. Dr. Wong has received personal compensation for serving as an employee of Biogen. Dr. Wong has stock in Biogen. Dr. Sidorenko has received personal compensation for serving as an employee of Actelion Pharmaceuticals Ltd, a Janssen Pharmaceutical company of Johnson&Johnson. Dr. Sidorenko has stock in Johnson&Johnson. Dr. Lublin has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Roche/Genentech. Dr. Lublin has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Biogen. Dr. Lublin has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Neurogene. Dr. Lublin has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Novartis. Dr. Lublin has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Medimmune/Viela Bio/Horizon. Dr. Lublin has received personal...
- Open Access
High-dimensional immune profiling of dimethyl fumarate and ocrelizumab in multiple sclerosis
Background: Dimethyl fumarate (DMF) and ocrelizumab are two effective immunomodulators for multiple sclerosis (MS) with distinct mechanisms of action. Identifying overlapping therapeutic effects between both agents may elucidate common pathways in preventing disease activity. Objectives: In this study we analyzed cytokine and immune-profiling data to evaluate the similarities and differences between the two disease-modifying therapies for MS. Methods : Plasma and PBMCs from MS patients were collected at baseline, 3 months and 6 months after treatment with DMF (n=16) and ocrelizumab (n=13). Immunophenotyping was performed with mass cytometry (CyTOF) and analyzed with gating based on cell surface markers. Cytokine analysis from plasma was performed with Olink assays and analyzed with linear mixed effects models. Results: DMF reduced both effector T and memory B cell populations while increasing CD56 bright natural killer (NK) cells. Ocrelizumab exerted its main immunomodulatory effect by reducing the frequency of all B cells and increasing frequency of NK cells. At 6 months, naive B-cells began to reconstitute; however, memory B cells remain depleted. DMF treatment was associated with a significant reduction of plasma cytokines involved in inflammatory pathways, such as IL-6, IL-12, and Dectin-1 signaling. In addition, DMF lowered plasma cytokines that are dysregulated in psoriasis and involved in allograft rejection pathways. Ocrelizumab treatment led to the upregulation of neurotropic proteins in the plasma of MS patients, including proteins involved in NAD+ biosynthesis and tryptophan catabolism. Conclusion: Our high-dimensional immunophenotyping results suggest that to exert their effects on MS patients, DMF and ocrelizumab both increase NK cells in addition to affecting different immune cell populations and cytokine pathways. Detecting similarities between the mechanisms of the two drugs may contribute to identifying more specific therapeutic targets.
Open AccessHigh-dimensional immune profiling of dimethyl fumarate and ocrelizumab in multiple sclerosis
Background: Dimethyl fumarate (DMF) and ocrelizumab are two effective immunomodulators for multiple sclerosis (MS) with distinct mechanisms of action. Identifying overlapping therapeutic effects between both agents may elucidate common pathways in preventing disease activity. Objectives: In this study we analyzed cytokine and immune-profiling data to evaluate the similarities and differences between the two disease-modifying therapies for MS. Methods : Plasma and PBMCs from MS patients were collected at baseline, 3 months and 6 months after treatment with DMF (n=16) and ocrelizumab (n=13). Immunophenotyping was performed with mass cytometry (CyTOF) and analyzed with gating based on cell surface markers. Cytokine analysis from plasma was performed with Olink assays and analyzed with linear mixed effects models. Results: DMF reduced both effector T and memory B cell populations while increasing CD56 bright natural killer (NK) cells. Ocrelizumab exerted its main immunomodulatory effect by reducing the frequency of all B cells and increasing frequency of NK cells. At 6 months, naive B-cells began to reconstitute; however, memory B cells remain depleted. DMF treatment was associated with a significant reduction of plasma cytokines involved in inflammatory pathways, such as IL-6, IL-12, and Dectin-1 signaling. In addition, DMF lowered plasma cytokines that are dysregulated in psoriasis and involved in allograft rejection pathways. Ocrelizumab treatment led to the upregulation of neurotropic proteins in the plasma of MS patients, including proteins involved in NAD+ biosynthesis and tryptophan catabolism. Conclusion: Our high-dimensional immunophenotyping results suggest that to exert their effects on MS patients, DMF and ocrelizumab both increase NK cells in addition to affecting different immune cell populations and cytokine pathways. Detecting similarities between the mechanisms of the two drugs may contribute to identifying more specific therapeutic targets.
- Top Cited PapersOpen Access
- 1 February 2022
- Published by Oxford University Press (OUP) in Brain
- Vol. 145 (9) , 3147-3161
How patients with multiple sclerosis acquire disability
Patients with multiple sclerosis acquire disability either through relapse-associated worsening (RAW) or progression independent of relapse activity (PIRA). This study addresses the relative contribution of relapses to disability worsening over the course of the disease, how early progression begins and the extent to which multiple sclerosis therapies delay disability accumulation. Using the Novartis-Oxford multiple sclerosis (NO.MS) data pool spanning all multiple sclerosis phenotypes and paediatric multiple sclerosis, we evaluated ∼200 000 Expanded Disability Status Scale (EDSS) transitions from >27 000 patients with ≤15 years follow-up. We analysed three datasets: (i) A full analysis dataset containing all observational and randomized controlled clinical trials in which disability and relapses were assessed (n = 27 328); (ii) all phase 3 clinical trials (n = 8346); and (iii) all placebo-controlled phase 3 clinical trials (n = 4970). We determined the relative importance of RAW and PIRA, investigated the role of relapses on all-cause disability worsening using Andersen-Gill models and observed the impact of the mechanism of worsening and disease-modifying therapies on the time to reach milestone disability levels using time continuous Markov models. PIRA started early in the disease process, occurred in all phenotypes and became the principal driver of disability accumulation in the progressive phase of the disease. Relapses significantly increased the hazard of all-cause disability worsening events; following a year in which relapses occurred (versus a year without relapses), the hazard increased by 31–48% (all P < 0.001). Pre-existing disability and older age were the principal risk factors for incomplete relapse recovery. For placebo-treated patients with minimal disability (EDSS 1), it took 8.95 years until increased limitation in walking ability (EDSS 4) and 18.48 years to require walking assistance (EDSS 6). Treating patients with disease-modifying therapies delayed these times significantly by 3.51 years (95% confidence limit: 3.19, 3.96) and 3.09 years (2.60, 3.72), respectively. In patients with relapsing-remitting multiple sclerosis, those who worsened exclusively due to RAW events took a similar length of time to reach milestone EDSS values compared with those with PIRA events; the fastest transitions were observed in patients with PIRA and superimposed relapses. Our data confirm that relapses contribute to the accumulation of disability, primarily early in multiple sclerosis. PIRA begins in relapsing-remitting multiple sclerosis and becomes the dominant driver of disability accumulation as the disease evolves. Pre-existing disability and older age are the principal risk factors for further disability accumulation. The use of disease-modifying therapies delays disability accrual by years, with the potential to gain time being highest in the earliest stages of multiple sclerosis.
- 1 February 2022
- Published by Oxford University Press (OUP) in Brain
- Vol. 145 (9) , 3147-3161
Top Cited PapersOpen AccessHow patients with multiple sclerosis acquire disability
Patients with multiple sclerosis acquire disability either through relapse-associated worsening (RAW) or progression independent of relapse activity (PIRA). This study addresses the relative contribution of relapses to disability worsening over the course of the disease, how early progression begins and the extent to which multiple sclerosis therapies delay disability accumulation. Using the Novartis-Oxford multiple sclerosis (NO.MS) data pool spanning all multiple sclerosis phenotypes and paediatric multiple sclerosis, we evaluated ∼200 000 Expanded Disability Status Scale (EDSS) transitions from >27 000 patients with ≤15 years follow-up. We analysed three datasets: (i) A full analysis dataset containing all observational and randomized controlled clinical trials in which disability and relapses were assessed (n = 27 328); (ii) all phase 3 clinical trials (n = 8346); and (iii) all placebo-controlled phase 3 clinical trials (n = 4970). We determined the relative importance of RAW and PIRA, investigated the role of relapses on all-cause disability worsening using Andersen-Gill models and observed the impact of the mechanism of worsening and disease-modifying therapies on the time to reach milestone disability levels using time continuous Markov models. PIRA started early in the disease process, occurred in all phenotypes and became the principal driver of disability accumulation in the progressive phase of the disease. Relapses significantly increased the hazard of all-cause disability worsening events; following a year in which relapses occurred (versus a year without relapses), the hazard increased by 31–48% (all P < 0.001). Pre-existing disability and older age were the principal risk factors for incomplete relapse recovery. For placebo-treated patients with minimal disability (EDSS 1), it took 8.95 years until increased limitation in walking ability (EDSS 4) and 18.48 years to require walking assistance (EDSS 6). Treating patients with disease-modifying therapies delayed these times significantly by 3.51 years (95% confidence limit: 3.19, 3.96) and 3.09 years (2.60, 3.72), respectively. In patients with relapsing-remitting multiple sclerosis, those who worsened exclusively due to RAW events took a similar length of time to reach milestone EDSS values compared with those with PIRA events; the fastest transitions were observed in patients with PIRA and superimposed relapses. Our data confirm that relapses contribute to the accumulation of disability, primarily early in multiple sclerosis. PIRA begins in relapsing-remitting multiple sclerosis and becomes the dominant driver of disability accumulation as the disease evolves. Pre-existing disability and older age are the principal risk factors for further disability accumulation. The use of disease-modifying therapies delays disability accrual by years, with the potential to gain time being highest in the earliest stages of multiple sclerosis.
- 1 April 2021
- Published by Elsevier in Multiple Sclerosis and Related Disorders
- Vol. 49, 102715
Pandemic forward: Lessons learned and expert perspectives on multiple sclerosis care in the COVID-19 era
- 1 April 2021
- Published by Elsevier in Multiple Sclerosis and Related Disorders
- Vol. 49, 102715
Pandemic forward: Lessons learned and expert perspectives on multiple sclerosis care in the COVID-19 era
- Open Access
- 16 June 2020
- Published by Wolters Kluwer Health in Neurology
- Vol. 94 (24) , 1088-1092
The 2013 clinical course descriptors for multiple sclerosis
The clinical courses of multiple sclerosis were defined in 1996 and refined in 2013 to provide a time-based assessment of the current status of the individual. These definitions have been successfully used by clinicians, clinical trialists, and regulatory authorities. Recent regulatory decisions produced variations and discrepancies in the use of the clinical course descriptions. We provide here a clarification of the concepts underlying these descriptions and restate the principles used in their development. Importantly, we highlight the critical importance of time framing the disease course modifiers activity and progression and clarify the difference between the terms worsening and progressing.
- 16 June 2020
- Published by Wolters Kluwer Health in Neurology
- Vol. 94 (24) , 1088-1092
Open AccessThe 2013 clinical course descriptors for multiple sclerosis
The clinical courses of multiple sclerosis were defined in 1996 and refined in 2013 to provide a time-based assessment of the current status of the individual. These definitions have been successfully used by clinicians, clinical trialists, and regulatory authorities. Recent regulatory decisions produced variations and discrepancies in the use of the clinical course descriptions. We provide here a clarification of the concepts underlying these descriptions and restate the principles used in their development. Importantly, we highlight the critical importance of time framing the disease course modifiers activity and progression and clarify the difference between the terms worsening and progressing.